1: Ding Y, Chow SH, Chen J, Brun APL, Wu CM, Duff AP, Wang Y, Song J, Wang JH,
Wong VHY, Zhao D, Nishimura T, Lee TH, Conn CE, Hsu HY, Bui BV, Liu GS, Shen HH.
Targeted delivery of LM22A-4 by cubosomes protects retinal ganglion cells in an
experimental glaucoma model. Acta Biomater. 2021 May;126:433-444. doi:
10.1016/j.actbio.2021.03.043. Epub 2021 Mar 24. PMID: 33774200.
2: Fletcher JL, Dill LK, Wood RJ, Wang S, Robertson K, Murray SS, Zamani A,
Semple BD. Acute treatment with TrkB agonist LM22A-4 confers neuroprotection and
preserves myelin integrity in a mouse model of pediatric traumatic brain injury.
Exp Neurol. 2021 May;339:113652. doi: 10.1016/j.expneurol.2021.113652. Epub 2021
Feb 18. Erratum in: Exp Neurol. 2021 Sep;343:113790. PMID: 33609501.
3: Nguyen HTH, Wood RJ, Prawdiuk AR, Furness SGB, Xiao J, Murray SS, Fletcher
JL. TrkB Agonist LM22A-4 Increases Oligodendroglial Populations During Myelin
Repair in the Corpus Callosum. Front Mol Neurosci. 2019 Aug 27;12:205. doi:
10.3389/fnmol.2019.00205. PMID: 31507374; PMCID: PMC6718610.
4: Yu G, Wang W. Protective effects of LM22A-4 on injured spinal cord nerves.
Int J Clin Exp Pathol. 2015 Jun 1;8(6):6526-32. PMID: 26261531; PMCID:
PMC4525865.
5: Kajiya M, Takeshita K, Kittaka M, Matsuda S, Ouhara K, Takeda K, Takata T,
Kitagawa M, Fujita T, Shiba H, Kurihara H. BDNF mimetic compound LM22A-4
regulates cementoblast differentiation via the TrkB-ERK/Akt signaling cascade.
Int Immunopharmacol. 2014 Apr;19(2):245-52. doi: 10.1016/j.intimp.2014.01.028.
Epub 2014 Feb 11. PMID: 24530412.
6: Fletcher JL, Dill LK, Wood RJ, Wang S, Robertson K, Murray SS, Zamani A,
Semple BD. Corrigendum to "Acute treatment with TrkB agonist LM22A-4 confers
neuroprotection and preserves myelin integrity in a mouse model of pediatric
traumatic brain injury" [Experimental Neurology 339 (2021): 113652]. Exp Neurol.
2021 Sep;343:113790. doi: 10.1016/j.expneurol.2021.113790. Epub 2021 Jun 26.
Erratum for: Exp Neurol. 2021 May;339:113652. PMID: 34187696.